Sandoz Group AG (LON:0SAN)
London · Delayed Price · Currency is GBP · Price in CHF | Market Cap | 26.88B +41.0% |
| Revenue (ttm) | 8.29B +7.4% |
| Net Income | 679.10M |
| EPS | 1.55 |
| Shares Out | n/a |
| PE Ratio | 39.58 |
| Forward PE | 20.27 |
| Dividend | 0.76 (1.26%) |
| Ex-Dividend Date | Apr 13, 2026 |
| Volume | 11,504 |
| Open | 67.70 |
| Previous Close | 67.37 |
| Day's Range | 67.06 - 68.08 |
| 52-Week Range | 44.01 - 74.70 |
| Beta | 0.50 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland. [Read more]
News
Sandoz Secures Brazil Approval For New Semaglutide Treatment Option
(RTTNews) - Sandoz Group AG (SDZNY) a company focused on affordable medicine, announced that Brazil's health regulator ANVISA has granted marketing authorization for Owozy (semaglutide), a new treatme...
Generic drug sector seeks policy fixes after Trump tariff threat
The generic drug market still faces structural and purchasing hurdles despite strong U.S. growth, an industry group noted on Wednesday, after President Donald Trump said imported generic medicines w...
Trump Proposes 200% Generic Drug Tariffs, Sandoz Shares Drop 4.2%
Trump Proposes 200% Generic Drug Tariffs, Sandoz Shares Drop 4.2%
Generic drugmaker Sandoz to engage with US after Trump tariff threat
Swiss generic drugmaker Sandoz said on Wednesday it would continue discussions with policymakers after U.S. President Donald Trump threatened the industry with steep tariffs unless drugmakers manufa...
Europe optimized its supply chains for cost. Now it must pay for resilience
Richard Saynor, CEO of Fortune 500 Europe company, Sandoz Group, and manufacturer of generic medicines, argues resilience requires investment that markets often fail to reward
Sandoz announces U.S. FDA accepted for review two ANDAs for tirzepatide
Sandoz (SDZNY) announces that the US Food and Drug Administration, FDA, has accepted for review two Abbreviated New Drug Applications, ANDAs, for generic versions of tirzepatide. The ANDAs seek approv...
FDA set to review Sandoz's generic GLP-1s
The U.S. Food and Drug Administration has agreed to review Swiss generics drugmaker Sandoz's two generic tirzepatide GLP-1s that, if approved, would rival obesity drugs made by Eli Lilly.
Generic drugmaker Sandoz files anti-dumping complaint about Chinese antibiotics imports
Swiss generic drugmaker Sandoz filed a draft anti-dumping complaint with the European Commission over Chinese imports of the antibiotic ingredient amoxicillin, part of the penicillin family, the co...
Sandoz confirms the EC granted marketing authorization for Bysumlog, Dazparda
Sandoz (SDZNY) confirms that the European Commission, EC, has granted marketing authorization for Bysumlog and Dazparda. The two biosimilar insulins, for injection in prefilled pens, are developed by ...
Sandoz CEO Says Size of Weight-Loss Generics Market Is Unknown
Switzerland's Sandoz sees Canada and Brazil markets as testing grounds before semaglutide goes off patent in Europe and the U.S. in the 2030s.
Sandoz upgraded to Overweight from Equal Weight at Barclays
Barclays upgraded Sandoz (SDZNY) to Overweight from Equal Weight with an unchanged price target of CHF 75. The firm finds the stock’s valuation “compelling” given Sandoz’s accelerating sales growth th...
Sandoz price target lowered to CHF 65 from CHF 70 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Sandoz (SDZNY) to CHF 65 from CHF 70 and keeps a Hold rating on the shares.
Sandoz Group AG Earnings Call Transcript: Q1 2026
Q1 2026 saw robust biosimilar-driven growth, with net sales up 11% headline and 3% at constant currencies, and biosimilars now 31% of sales. Generics declined due to portfolio pruning and B2B headwinds, but stabilization is expected from Q2. Full-year guidance for mid to high single-digit sales growth and margin expansion is reaffirmed.
Sandoz Group AG Slides: Q1 2026
Sandoz Group AG has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 29, 2026.
Sandoz Group AG Earnings release: Q1 2026
Sandoz Group AG released its Q1 2026 earnings on April 29, 2026, summarizing the period's financial results.
Sandoz price target raised to CHF 75 from CHF 66 at JPMorgan
JPMorgan analyst Sophia Graeff Buhl Nielsen raised the firm’s price target on Sandoz (SDZNY) to CHF 75 from CHF 66 and keeps an Overweight rating on the shares. Published first…
Sandoz initiated with a Buy at Goldman Sachs
Goldman Sachs initiated coverage of Sandoz (SDZNY) with a Buy rating and CHF 74 price target The firm views Sandoz as a global leader in the generics and biosimilar industry.
Sandoz downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital analyst Natalia Webster downgraded Sandoz (SDZNY) to Sector Perform from Outperform with a price target of CHF 65, up from CHF 53. The firm cites valuation for the…
Sandoz announces partnership agreement with Samsung Bioepis
Sandoz (SDZNY) announced a major license, development and commercialization partnership agreement with Samsung Bioepis. The agreement paves the way for the two companies to partner on up to five biosi...
Sandoz price target raised to CHF 62 from CHF 55 at Berenberg
Berenberg raised the firm’s price target on Sandoz (SDZNY) to CHF 62 from CHF 55 and keeps a Hold rating on the shares.
Sandoz downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank downgraded Sandoz (SDZNY) to Hold from Buy with a CHF 70 price target
Sandoz downgraded to Equal Weight from Overweight at Barclays
Barclays downgraded Sandoz (SDZNY) to Equal Weight from Overweight with a price target of CHF 75, up from CHF 70. The firm cites valuation for the downgrade with the shares…
Sandoz Shares Jump on Improved Guidance
Stock rose 6.4% after the company bumped up its revenue guidance thanks to growth in its biosimilar product range.
Sandoz Group AG Earnings Call Transcript: Q4 2025
Net sales grew 5% to $11.1B in 2025, with biosimilars now 30% of sales and core EBITDA margin up to 21.7%. Strong launches, strategic acquisitions, and robust pipeline support mid to high single-digit sales growth in 2026, despite ongoing generics pricing pressures.
Sandoz Group AG Earnings release: Q4 2025
Sandoz Group AG released its Q4 2025 earnings on February 25, 2026, summarizing the period's financial results.